Amiloride and the Diabetic Kidney

Overview

Journal J Hypertens

Specialty Cardiology & Vascular Diseases

Date 2016 Jun 30

PMID 27355999

Citations 1

Authors

Mark C Chappell

Affiliations

Soon will be listed here.

Citing Articles

Electrocardiographic findings in an elderly patient before and after resolution of iatrogenic hyperkalemia.

Xing Y, Li H, Jiang C, Huang W, Feng F, Sun Y J Geriatr Cardiol. 2020; 17(9):589-592.

PMID: 33117425 PMC: 7568042. DOI: 10.11909/j.issn.1671-5411.2020.09.005.

References

Rossier B, Stutts M . Activation of the epithelial sodium channel (ENaC) by serine proteases. Annu Rev Physiol. 2008; 71:361-79. DOI: 10.1146/annurev.physiol.010908.163108. View

Passero C, Hughey R, Kleyman T . New role for plasmin in sodium homeostasis. Curr Opin Nephrol Hypertens. 2009; 19(1):13-9. PMC: 2894526. DOI: 10.1097/MNH.0b013e3283330fb2. View

Andersen R, Buhl K, Jensen B, Svenningsen P, Friis U, Jespersen B . Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC. Pediatr Nephrol. 2013; 28(8):1227-34. DOI: 10.1007/s00467-013-2439-2. View

Wei C, Moller C, Altintas M, Li J, Schwarz K, Zacchigna S . Modification of kidney barrier function by the urokinase receptor. Nat Med. 2007; 14(1):55-63. DOI: 10.1038/nm1696. View

Andersen H, Friis U, Hansen P, Svenningsen P, Henriksen J, Jensen B . Diabetic nephropathy is associated with increased urine excretion of proteases plasmin, prostasin and urokinase and activation of amiloride-sensitive current in collecting duct cells. Nephrol Dial Transplant. 2015; 30(5):781-9. DOI: 10.1093/ndt/gfu402. View

McDonough A, Nguyen M . Maintaining Balance Under Pressure: Integrated Regulation of Renal Transporters During Hypertension. Hypertension. 2015; 66(3):450-5. PMC: 4943879. DOI: 10.1161/HYPERTENSIONAHA.115.04593. View

Schild L, Canessa C, Shimkets R, Gautschi I, Lifton R, Rossier B . A mutation in the epithelial sodium channel causing Liddle disease increases channel activity in the Xenopus laevis oocyte expression system. Proc Natl Acad Sci U S A. 1995; 92(12):5699-703. PMC: 41764. DOI: 10.1073/pnas.92.12.5699. View

Buhl K, Oxlund C, Friis U, Svenningsen P, Bistrup C, Jacobsen I . Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro. J Hypertens. 2014; 32(8):1672-7. DOI: 10.1097/HJH.0000000000000216. View

Trimarchi H, Canzonieri R, Muryan A, Schiel A, Araoz A, Paulero M . Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease. Case Rep Nephrol. 2016; 2016:1492743. PMC: 4749773. DOI: 10.1155/2016/1492743. View

10.

Staehr M, Buhl K, Andersen R, Svenningsen P, Nielsen F, Hinrichs G . Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine. Am J Physiol Renal Physiol. 2015; 309(3):F235-41. DOI: 10.1152/ajprenal.00138.2015. View

11.

Warnock D, Rossier B . Renal sodium handling: the role of the epithelial sodium channel. J Am Soc Nephrol. 2005; 16(11):3151-3. DOI: 10.1681/ASN.2005080886. View

12.

Zhang B, Xie S, Shi W, Yang Y . Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. Nephrol Dial Transplant. 2011; 27(5):1746-55. DOI: 10.1093/ndt/gfr612. View

13.

Hansson J, Schild L, Lu Y, Wilson T, Gautschi I, Shimkets R . A de novo missense mutation of the beta subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity. Proc Natl Acad Sci U S A. 1995; 92(25):11495-9. PMC: 40428. DOI: 10.1073/pnas.92.25.11495. View

14.

Andersen H, Hansen P, Bistrup C, Nielsen F, Henriksen J, Jensen B . Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy. J Hypertens. 2016; 34(8):1621-9. DOI: 10.1097/HJH.0000000000000967. View

15.

Lifton R, Gharavi A, Geller D . Molecular mechanisms of human hypertension. Cell. 2001; 104(4):545-56. DOI: 10.1016/s0092-8674(01)00241-0. View

16.

Xu L, Chi N, Shi W . Amiloride, a urokinase-type plasminogen activator receptor (uTPA) inhibitor, reduces proteinurea in podocytes. Genet Mol Res. 2015; 14(3):9518-29. DOI: 10.4238/2015.August.14.15. View

17.

Svenningsen P, Andersen H, Nielsen L, Jensen B . Urinary serine proteases and activation of ENaC in kidney--implications for physiological renal salt handling and hypertensive disorders with albuminuria. Pflugers Arch. 2014; 467(3):531-42. DOI: 10.1007/s00424-014-1661-5. View